A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2292-2300

  Gilbert, Jill ^a   Baker, Sharyn D ^a   Bowling, M Katherine ^a   Grochow, Louise ^a   Figg, W Douglas ^b   Zabelina, Yelena ^a   Donehower, Ross C ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; HYPOCALCEMIA; MALE; NAUSEA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FATIGUE; FEMALE; GLUTAMINE; HUMANS; HYPOCALCEMIA; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NERVOUS SYSTEM DISEASES; PHENYLACETATES; PHENYLBUTYRATES; TREATMENT OUTCOME; VOMITING;

EID: 0034885248     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
2. Transcriptional upregulation of TGF-α by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells
3. Transcriptional upregulation of γ globin by phenylbutyrate and analogous aromatic fatty acids
4. Phenylbutyrate has pleiotropic effects on gene transcription and inhibits telomerase activity in human prostate cancer
5. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
6. Activation of the human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogues
7. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
8. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase
9. Induced differentiation, the cell cycle, and the treatment of cancer
10. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion
11. Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency
12. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis
13. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: Review of nine cases
14. Induction of fetal hemoglobin production in subjects with sickle cell anemia with oral sodium phenylbutyrate
15. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells
16. Phenylbutyrate (PB) for refractory solid tumors. Phase I clinical and pharmacologic evaluation of intravenous and oral PB
17. Clinical development of sodium phenylbutyrate as a putative differentiating agent in myeloid malignancies
18. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
19. The nuclear receptors PPARS as novel targets in differentiation therapy: Activation by phenylacetate and phenylbutyrate
20. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer